Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEPTUNE-17
2022-502313-28-00Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in diabetic polyneuropathy (DPN) comparing GSK3858279 with Placebo (2 arms). Primary endpoint: Change from baseline in the weekly average of average daily pain intensity at Week 12. Started Jul 2023; status: completed.
02
Drugs
GSK3858279
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on 2022-502313-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502313-28-00.